Stay updated with breaking news from Global External. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
FDA assessment concludes that the Phase II combination trial, LEGEND, may proceed The initiation of the trial is planned for H1 2022 and the publication of topline results is expected for H2 2023 ... | March 8, 2022
FDA assessment concludes that the Phase II combination trial, LEGEND, may proceed The initiation of the trial is planned for H1 2022 and the publication of topline results is expected for H2 2023
Inventiva announces that its IND application for the Phase II combination trial with lanifibranor and empagliflozin in patients with NASH and T2D has been accepted by the FDA - read this article along with other careers information, tips and advice on BioSpace
Investegate announcements from INVENTIVA, Inventiva reports its 2021 Full-Year Results: key milestones achieved with lanifibranor in NASH and cedirogant in psoriasis
Investegate announcements from INVENTIVA, Inventiva announces participation at several conferences in March 2022